Evidence map›Paper›PMID 33007379›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2020

Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?

T Grinda, S Delaloge

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Cytotoxic and targeted therapy for BRCA1/2-driven cancers.Hereditary cancer in clinical practice · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

T GrindaDepartment of Cancer Medicine, Gustave Roussy, Villejuif, France.
S DelalogeDepartment of Cancer Medicine, Gustave Roussy, Villejuif, France; Inserm U931, Cancer Biomarkers, Paris Saclay University, Gustave Roussy, Villejuif, France. Electronic address: suzette.delaloge@gustaveroussy.fr.
Inserm · FRInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinGerm CellsHumansPhthalazinesBRCA1 ProteinBRCA1 protein, humanPhthalazinesPoly(ADP-ribose) Polymerase Inhibitorstalazoparib

Identifiers

PMID33007379
OpenAlexW3091426296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.